Processa Pharmaceuticals, Inc. Finance Lease, Liability, to be Paid, Year Two
Processa Pharmaceuticals, Inc. (PCSA) had Finance Lease, Liability, to be Paid, Year Two of $571 as of 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo · last filed 2025-03-20
- 2024-12-31: Finance Lease, Liability, to be Paid, Year Two $571.00.
- 2024-09-30: Finance Lease, Liability, to be Paid, Year Two $488.00.
- 2024-06-30: Finance Lease, Liability, to be Paid, Year Two $488.00.
- 2024-03-31: Finance Lease, Liability, to be Paid, Year Two $488.00.
| Period end | Finance Lease, Liability, to be Paid, Year Two |
|---|---|
| 2024-12-31 | $571.00 10-K · filed 2025-03-20 |
| 2024-09-30 | $488.00 10-Q · filed 2024-10-30 |
| 2024-06-30 | $488.00 10-Q · filed 2024-08-13 |
| 2024-03-31 | $488.00 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |